Aveo Oncology

Aveo announces executive transition, corporate restructuring

Thursday, January 8, 2015

Aveo Oncology, based in Cambridge, Mass., has appointed Michael P. Bailey as the company’s president, CEO and director, effective immediately. Aveo also said it will eliminate the company’s internal research function, as well as certain corporate support positions, to align corporate resources with the company’s future strategic plans, focusing on advancement of its pipeline in the clinical setting.

[Read More]

Aveo Oncology to restructure, cut workforce 62%

Friday, June 7, 2013

Aveo Oncology, a cancer therapeutics company, is restructuring to refocus its efforts and resources on the ongoing clinical development of tivozanib in colorectal and breast cancer, as well as advance key pipeline and preclinical assets. This restructuring is expected to extend the company’s cash runway for at least two years, beyond anticipated data read-outs from ongoing trials of tivozanib and AV-203.

[Read More]

Aveo refocuses on tivozanib, cuts 17% of workforce

Tuesday, October 30, 2012

Aveo Oncology, a cancer therapeutics company based in Cambridge, Mass., has announced a strategic restructuring designed to optimize resources and reduce expenses to ensure Aveo is well positioned for a successful launch of tivozanib in renal cell carcinoma (RCC) and continued development in other cancer types, while maintaining a focused research engine.

[Read More]